Related Experiment Video

Updated: Aug 14, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors

Aditya Raj1, Adarsh Kumar1, Ankit Kumar Singh1

  • 1Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.

Anti-Cancer Agents in Medicinal Chemistry
|January 17, 2023
PubMed

Insights

Quinazoline derivatives show promise as inhibitors of phosphoinositide 3-kinase (PI3K), a key target in cancer therapy, particularly for multiple myeloma. This study reviews their synthesis, anticancer mechanisms, and structure-activity relationships for improved drug design.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Phosphoinositide 3-kinase (PI3K) is crucial for cellular functions and implicated in plasma cell cancer (multiple myeloma) via the PI3K/AKT signaling pathway.
  • Quinazoline derivatives represent a significant class of compounds investigated for their PI3K inhibitory potential.

Purpose of the Study:

  • To review synthetic strategies for quinazoline derivatives targeting PI3K.
  • To analyze the anticancer mechanisms of action for these compounds.
  • To explore structure-activity relationships to guide the development of novel, isoform-selective PI3K inhibitors.

Main Methods:

  • Literature review of synthetic approaches for quinazoline-based PI3K inhibitors.
  • Analysis of reported data on anticancer mechanisms and efficacy.
  • Structure-activity relationship (SAR) analysis of existing quinazoline derivatives.

Main Results:

  • Several quinazoline-based PI3K inhibitors are FDA-approved (e.g., Lapatinib, Idelalisib) or in clinical trials.
  • These compounds demonstrate diverse mechanisms for inhibiting PI3K signaling.
  • SAR studies provide insights into optimizing potency and selectivity.

Conclusions:

  • Quinazoline derivatives are a valuable scaffold for developing PI3K inhibitors in oncology.
  • Further research into synthesis and SAR can lead to more effective and selective anticancer agents.
  • This review aids researchers in designing next-generation PI3K-targeted therapies for hematological malignancies.
Keywords:
CancerPI3KSARmTOR pathwaysmechanism of actionquinazoline

More Related Videos

Facile Preparation of 4-Substituted Quinazoline Derivatives11:51

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

12.0K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
840
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
631
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K